Distribution Practices for Retail Note Offerings

Every structured note you have ever purchased traveled through a distribution pipeline designed to maximize issuer and broker economics -- not your risk-adjusted return. The U.S. structured notes market hit a record $149.4 billion in 2024 (a 46% year-over-year jump), and the vast majority of that volume flowed through a chain where every participant gets paid before you see a single dollar of return. Understanding that chain -- who earns what, where costs hide, and why your advisor recommends one product over another -- is the single most important skill you can develop as a structured note investor. The counter-move isn't avoiding structured notes entirely (they can serve real portfolio purposes). It's learning to read the distribution pipeline the way the people who built it read it.

How the Sausage Gets Made (The Distribution Chain)

The structured note business has a deceptively simple supply chain. An issuer (typically a major bank like JPMorgan, Goldman Sachs, or Barclays) designs the note and bears the credit risk. An arranger (often the same bank's structuring desk) prices the embedded options and sets the terms. A distributor (the broker-dealer or wirehouse) sells the note to end investors. And a financial advisor -- the person sitting across from you -- recommends the product.

Here is what that chain actually looks like in dollar terms on a typical $1,000 note:

Add those up: 1.15% to 4.75% leaves the building before the note even starts working for you. On a two-year note, Barclays' contingent coupon notes in 2024 carried an effective expense ratio of roughly 2.3% per year. Some products run as high as 4.59% in total markups.

The point is: when someone offers you a "10% coupon" on a structured note, a meaningful chunk of the option premium that could have gone toward higher coupons or deeper barriers was instead diverted into the distribution chain. You are not getting the full economic value of the risk you are taking.

Where the Fees Actually Hide (Embedded Cost Architecture)

Unlike a mutual fund with a published expense ratio or an ETF with a transparent bid-ask spread, structured note costs are baked into the product design itself. This is not accidental -- it is architectural.

When a bank structures a note, it buys hedging instruments (options, swaps) at institutional prices and sells you the packaged product at retail prices. The difference between the fair value of the components and the issue price you pay is the bank's total take. The SEC has flagged this specifically: the estimated value of a note on its pricing date is almost always disclosed as less than the issue price (often 2-5% less on day one).

Think about what that means. You buy a note at $1,000. The bank's own pricing supplement says it is worth approximately $960-$980 at issuance. You are underwater from the moment you invest.

Three layers of cost embed themselves into that gap:

Layer 1: The structuring margin. The bank prices options at mid-market but builds the note using less favorable strikes or barriers than the option budget would support at institutional pricing. You never see this because you never see the component pricing (that is the whole point of packaging).

Layer 2: The distribution concession. The bank pays your broker-dealer a fee, and your broker-dealer pays your advisor a sales credit. These fees come directly out of the note's economics -- meaning your coupon is lower, your barrier is higher, or your participation rate is worse than it would be without them.

Layer 3: The hedging spread. The bank does not hedge at mid-market itself. It captures a spread on every hedge it executes, and that spread compounds across the multiple instruments required to replicate your note's payoff.

Why this matters: the total cost of a structured note is virtually impossible for a retail investor to calculate independently. The fees are not listed on a single line item. They are scattered across the structuring, distribution, and hedging functions. Estimates from industry sources put total all-in costs at 1.5% to 4%+ annually, but the range is wide precisely because transparency is low.

Your Advisor's Incentive Problem (Compensation Models That Shape Recommendations)

Here is the uncomfortable truth about structured note distribution: your advisor often earns more selling you a structured note than recommending an ETF or individual bond. The economics are not even close.

A typical advisory fee on a managed portfolio runs 1% per year. A structured note sale generates an immediate 1-2% commission (sometimes more) on the notional amount, with no ongoing management required. For an advisor managing $100 million in client assets, steering 10% of that into structured notes can generate $100,000-$200,000 in additional one-time commissions -- on top of their regular advisory fees.

The incentive distortion gets worse in specific scenarios:

Proprietary product bias. When your advisor works for a bank that also issues structured notes (think Morgan Stanley advisor selling Morgan Stanley-issued notes), the firm captures both the structuring margin and the distribution fee. FINRA has specifically flagged this as a conflict, noting that "sales of proprietary products may offer higher compensation rates than other products."

Shelf-space economics. Issuers compete for distribution by offering higher commissions to broker-dealers. A bank offering 2% distribution fees will get more shelf space than one offering 1%. Your advisor sees the products their firm has approved -- and the approval process is influenced by the economics the firm negotiated.

Trailing commissions as lock-in. Some notes pay advisors ongoing trailing fees of 0.1-0.5% per year. This creates an incentive to keep you in the note rather than recommending early exit (even when circumstances change), because the advisor's income stream depends on you holding.

The takeaway: under Regulation Best Interest (Reg BI), your advisor must act in your best interest -- but disclosure of conflicts alone does not satisfy that obligation. FINRA has been explicit: "Disclosure of conflicts alone does not satisfy the obligation to act in the retail investor's best interest." Ask your advisor directly: "What do you earn on this note versus a comparable ETF strategy?" The answer will be illuminating.

The Platform Revolution (And Its Limits)

The structured note market has been reshaped by technology platforms that promise greater transparency and access. Three platforms dominate:

Luma Financial Technologies (founded 2011) is the largest independent multi-issuer platform, used by broker-dealers, RIAs, and private banks. It raised $63 million in Series C funding in 2025, backed by Bank of America, Morgan Stanley, UBS, and TD Bank Group. Luma lets advisors compare notes across issuers and run lifecycle analytics.

Halo Investing (founded 2015, backed by Allianz) positions itself as a democratizer -- bringing structured notes and buffered ETFs to retail investors with minimums as low as $1,000. Previously, most structured note offerings required $50,000-$100,000 minimums. Halo's marketplace model allows advisors to shop across multiple issuers.

iCapital (which acquired Goldman Sachs' SIMON platform in 2022) distributed over $17.7 billion in structured investments in 2024 alone, primarily to RIAs, wirehouses, and independent broker-dealers. The SIMON acquisition was telling -- Goldman originally built the platform to help its own retail brokers offer structured notes, but competitors were slow to adopt a Goldman-owned tool (for obvious reasons).

These platforms genuinely improve transparency compared to the old model (where your advisor relied on a single issuer's sales desk and whatever terms that desk chose to offer). But understand the limits:

Platforms still earn fees. They charge issuers for distribution access, and those costs flow through to you in the note's economics. The platform is not free -- it is just a different toll booth on the same highway.

Comparison is not the same as fair pricing. Seeing three issuers' terms side-by-side helps, but all three are still embedding costs. You are choosing the least expensive option among products that are all more expensive than their component parts.

Access does not equal suitability. Lower minimums mean less sophisticated investors can now buy products that were previously restricted to high-net-worth clients (who presumably had advisors with deeper structuring knowledge). A $1,000 minimum does not make a complex barrier note appropriate for a beginning investor.

The practical takeaway: platforms are a net positive for investors, but they solve the comparison problem -- not the cost problem. Use them to shop, but do not mistake platform access for the kind of transparency that comes from understanding the underlying economics yourself.

The Liquidity Trap (What Happens When You Need Out Early)

This is where the distribution model inflicts its deepest wound on retail investors. A liquid secondary market for structured notes does not exist. The SEC, FINRA, and every honest practitioner will tell you the same thing: these are buy-and-hold-to-maturity instruments, and anything else is a gamble against the house.

If you need to sell before maturity, here is what you face:

The issuer is your only buyer. In most cases, the bank that issued your note is also the only entity willing to make a secondary market in it. They set the bid price. You have no competing quotes, no exchange-traded transparency, and no leverage (unless you hold a very large position, which creates a different set of problems).

The bid-ask spread is punishing. On liquid exchange-traded products, bid-ask spreads run 0.01-0.10%. On structured notes, spreads of 1-5% are common, and during market stress (precisely when you are most likely to want out), they can widen dramatically.

Early redemption penalties apply. Some notes carry explicit early redemption fees. Industry data from 2024 shows the average discount for early exit was 12-15% of notional value. In extreme cases, early exit penalties can reach up to 35% -- a staggering haircut that wipes out years of coupon income.

Why this matters: the distribution model sells you a product with a stated maturity of 12-24 months as though that is a moderate time commitment. But the illiquidity premium embedded in that product is enormous -- far larger than most investors realize at the point of sale. If there is any chance you will need the money before maturity, structured notes are the wrong vehicle. Full stop.

The Suitability Theater (How Recommendations Actually Get Made)

Regulation Best Interest requires your advisor to have a "reasonable basis" for recommending a structured note. In practice, this means documenting that the product matches your stated objectives, risk tolerance, and time horizon. The process sounds protective. The reality is more nuanced.

The check-the-box problem. Suitability assessments are largely standardized questionnaires. An advisor who wants to sell a note to a moderate-risk client can often frame the product as suitable by emphasizing the downside barrier ("you are protected down to 25%") while downplaying the barrier breach scenario (which could be catastrophic). The documentation supports the recommendation -- but the recommendation was made first, and the documentation followed.

The comparison gap. Reg BI requires that your advisor consider "reasonably available alternatives." But the definition of "reasonably available" is generous. An advisor at a wirehouse with a structured notes desk is not required to compare the note against a custom options strategy that would deliver similar exposure at lower cost (because the firm does not offer that as a product). The comparison set is limited to what the firm sells.

The understanding asymmetry. Your advisor may not fully understand the product either. Structured notes involve embedded derivatives, barrier mechanics, and issuer credit risk -- concepts that require quantitative training many advisors lack. The training provided by issuers is marketing-adjacent (focused on selling points, not risk analytics). When your advisor cannot independently price the note, they cannot independently assess whether its terms are fair.

The test: ask your advisor three questions before purchasing any structured note: (1) What is the estimated value of this note on the pricing date versus the issue price? (2) What would a comparable payoff cost using exchange-traded options? (3) What is the worst-case scenario, in dollar terms, on my specific investment amount? If they cannot answer all three confidently, the suitability process has failed regardless of what the paperwork says.

Real-World Example: Anatomy of a $100,000 Note Purchase

Your advisor recommends an 18-month autocallable note linked to the S&P 500. The headline terms look attractive: 10% annual contingent coupon, quarterly observation, 75% downside barrier, issued by a major bank.

Here is what the economics actually look like:

What you pay: $100,000 at par.

What the note is worth at issuance: approximately $96,000-$97,500 (per the issuer's own estimated value disclosure in the pricing supplement). You are $2,500-$4,000 underwater on day one.

Where the $2,500-$4,000 gap went:

• Structuring fee to the bank's desk: ~$500 (0.5%)
• Distribution fee to your broker-dealer: ~$1,500 (1.5%)
• Sales credit to your advisor: ~$1,000 (1.0%)
• Hedging spread retained by the bank: ~$500-$1,000

What happens if you need out at month 6: the bank bids your note at roughly $85,000-$88,000 (assuming flat markets). That is a 12-15% haircut for a six-month hold -- equivalent to an annualized cost of 24-30%.

What happens if the S&P drops 30%: your barrier is breached. You receive roughly $70,000 back at maturity. You lost $30,000 in principal plus you never received the 10% coupon (because the observation levels were not met). Meanwhile, a simple S&P 500 ETF position with a 30% decline would have lost the same amount -- but with no embedded fees, better liquidity, and the ability to hold for recovery.

The practical point: the structured note only outperforms in a narrow range of outcomes (moderate positive returns where the coupon is paid but the market does not rise enough to make a simple equity position superior). In most other scenarios -- strong rally, moderate decline, sharp decline -- you would have been better served by simpler instruments.

Detection Signals (How to Know the Distribution Machine Is Working on You)

You are likely being sold rather than advised if:

• Your advisor presents only the headline coupon without discussing estimated value at issuance (the gap between issue price and fair value)
• The recommendation came during a "limited offering window" that creates urgency (structured notes are issued continuously -- there is always another one)
• You cannot find a clear breakdown of total compensation your advisor and their firm receive on this specific product
• The comparison is always against cash or CDs (where the note looks great) rather than against a comparable options strategy or buffered ETF (where it looks less compelling)
• Your advisor describes the barrier as "protection" without quantifying the probability of barrier breach using historical data
• The phrase "principal protected" is used loosely (true principal protection only applies to specific note types, and even then is subject to issuer credit risk)

Mitigation Checklist (Tiered)

Essential (high ROI)

These five items catch the majority of distribution-related problems:

• Read the pricing supplement (not the marketing summary) and find the "Estimated Value" disclosure -- compare it to the issue price
• Ask for total compensation disclosure -- distribution fee plus sales credit plus any trailing commissions, in dollar terms on your specific investment
• Compare the note's payoff to a simple alternative (buffered ETF, covered call ETF, or direct options strategy) before committing
• Confirm you can hold to maturity -- if there is any chance you need the money early, do not buy the note
• Check the issuer's credit rating -- your note is an unsecured debt obligation, and you are taking bank credit risk on top of market risk

High-Impact (workflow and automation)

For investors who use structured notes regularly:

• Use a multi-issuer platform (Luma, Halo, or iCapital) to compare terms across at least three issuers for equivalent payoff structures
• Track your notes' estimated values over time -- some platforms provide ongoing mark-to-market, which reveals the true cost of early exit
• Cap structured note allocation at 10-15% of your liquid portfolio to manage concentration and liquidity risk
• Build a maturity ladder so that notes mature at staggered intervals, reducing the chance that you need to sell any single note early

Optional (for sophisticated investors)

If you have options experience or quantitative background:

• Price the embedded options independently using Black-Scholes or a free options calculator to estimate fair value versus the packaged product
• Monitor the issuer's CDS spread as a real-time measure of credit risk (rising CDS spreads mean your note's credit component is deteriorating)
• Negotiate terms directly if your investment size exceeds $500,000 -- custom notes allow you to reduce distribution fees by cutting out intermediaries

Next Step (Put This Into Practice)

The next time a structured note is recommended to you, do one thing before anything else: find the "Estimated Value of the Notes" section in the pricing supplement.

How to find it:

1. Ask your advisor for the preliminary pricing supplement (it is a legal requirement -- they must provide it)
2. Search the document for "estimated value" -- it is typically in the first 5-10 pages
3. Compare the estimated value to the issue price ($1,000 par)

What the gap tells you:

• Less than 2% gap ($980+ estimated value): Relatively lean distribution economics -- the note's terms are closer to fair value
• 2-4% gap ($960-$980): Standard distribution costs -- typical for wirehouse distribution, but worth comparing to alternatives
• Greater than 4% gap (below $960): Heavy distribution load -- the economics strongly favor the issuer and distributor over you

Action: if the gap exceeds 3%, ask your advisor to show you a comparable product from a competing issuer on a multi-issuer platform. If they cannot or will not, that tells you everything you need to know about whose interests are being served.